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Changes in endogenous cytokines, adhesion molecules and platelets during
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Summarv The aim of this study was to investigate mechanisms of anti-tumour activity and necrosis induced
bv combinations of tumour necrosis factor alpha (TNF-x) and interferon gamma (IFN-y). In a breast cancer
xenograft model, locally injected recombinant human TNF-a arrested growth of established tumours in the
absence of overt necrosis. Macroscopic necrosis occurred when rat IFN-y. which had no anti-tumour activity
as a single agent. was given systemically. Treatment with TNF-a and IFN-y caused focal engorgement of
tumour capillaries with erythrocytes. intravascular recruitnent of polymorphonuclear cells and platelet
adherence to the tumour vascular endothelium 4h after the combined treatment. This was followed by
destruction of tumour vascular endothelium and both necrosis and apoptosis of tumour cells. Concomitant
with these changes. semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis
revealed the increase of stromal (murine) mRNA levels for TNF-uF. TNF receptor 55 kDa. TNF receptor
75 kDa. intracellular adhesion molecule 1. vascular cell adhesion molecule 1, P-selectin and interleukin 6
(IL-6). Thus. the effect of the combined TNF-a and IFN-y therapy involved the selective destruction of the
tumour vasculature. death of tumour cells and increased expression of a series of stromal cvtokines. cytokine
receptors and adhesion molecules. which could be implicated in the observed events.
Keywords: tumour necrosis factor alpha. interferon gamma, human xenograft: platelets. cytokines
The concept of inducing haemorrhagic necrosis to treat
tumours was first investigated systematically by Coley (1893).
However, it was not until 1975 that a tumour-necrosing
activity in the sera of BCG-pnrmed endotoxin treated mice
was isolated (Carswell et al.. 1975). Since then, two molecules
responsible for this activity. TNF-a (cachectin) and TNF-P
(lymphotoxin). have been purified, cloned, and produced in
large amounts by recombinant technology (reviewed in
Beutler. 1992). Their availability allowed extensive studies,
both in animal models and clinical trials. Although initially
TNF--a was hailed as a potent anti-tumour treatment, it later
proved to induce only modest tumour responses accom-
panied by unacceptable side-effects (Feinberg et al., 1988).
Moreover, endogenous TNF-a has also been implicated in
tumour progression, particularly in ovarian cancer (Naylor et
al., 1993).
Potentiation of the anti-tumour actions of TNF--x was
obtained with IFN-y in a variety of murine tumours and
human tumour xenografts (Brouckaert et al., 1986; Fransen
et al.. 1986; Balkwill et al., 1987). Later, Thom et al. (1992)
reported improvement of the anti-tumour effect and higher
cure rate of MCA sarcomas treated with paralesional
administration of TNF-a. together with IFN-y. In recent
clinical experiments, high doses of locoregional TNF-a. com-
bined with systemic IFN-a and local chemotherapy, mediated
specific destruction of tumour vasculature, and complete
tumour regression, in a majority of patients with melanoma,
squamous cell carcinoma and soft tissue sarcoma, whose
tumours are accessible to isolated limb perfusion (ILP)
(Lienard et al., 1992; Eggermont et al., 1993). The impressive
anti-tumour effects of this treatment seem to be associated
with vascular-mediated damage (Renard et al.. 1994). This
treatment however remains controversial: other groups using
the same procotol have been unable to obtain similar results
(Vaglini et al., 1994).
These studies led us to develop an animal model reproduc-
ing some of the observed effects of TNF-a and IFN-y in ILP
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therapy. There are obviously differences between ILP with
human vascular administration of human TNF-a and human
IFN-y in a human host vs intratumoural injections of human
TNF-x and systemic administration of rat IFN-y in an
immunocompromised mouse. However, we used a xenogeneic
system to permit dissociation between effects on host and
tumour cells. We examined the actions of TNF-a and IFN-y
on tumour necrosis, tumour growth and survival. His-
tological changes were monitored and expression of stromal
cytokine, cytokine receptor and adhesion molecule mRNA
were followed within the murine host.
Materials and methods
Mice
Female pathogen-free nu nu mice of mixed genetic back-
ground were bred by the Imperial Cancer Research Fund
animal breeding unit, Clare Hall, Potters Bar, UK. They
were housed in negative pressure isolators and used for
experiments when 6-9 weeks old.
Tumours
The human breast mucoid carcinoma 1068 was originally
derived from a primary tumour (Balkwill et al., 1986) and
maintained by passage in mice at 6-8 week intervals.
Cvtokines
Recombinant human TNF-a kindly provided by BASF Knoll
(Maidenhead, Berkshire, UK), was more than 99% pure and
contained less than 0.125 EU mg-' endotoxin. The sp. act.
was 5 x 107 units mg-'. Recombinant rat IFN-y was pro-
vided by Roussel UCLAF (Romainville, France). It had a sp.
act. of I x 107 units mg-1. Endotoxin levels were less than
0.367 EU mg-'. TNF-a and IFN-y were diluted to the appro-
pnate concentration with calcium- and magnesium-free
phosphate-buffered saline (PBS) containing 3 mg ml-i bovine
serum albumin (BSA; Sigma, Dorset, UK) and stored in
single dose aliquots at - 70'C.An"mour ds od TNF-e and IFN-y in nv
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Experimental design
Established tumours were minced finely with scissors and
0.05 ml tumour suspension was injected subcutaneously (s.c.)
into a lateral site on each mouse. After 7-21 days when
tumours measured approximately 0.2-0.4 cm. therapy was
started. Each experimental group contained 7-8 mice bear-
ing a single tumour. Mice were given daily or weekly intra-
tumoural (i.t.) injections of 0.1 ml of the appropriate TNF-a
dose or PBS BSA control solution. Rat IFN-y (0.1 ml) at the
appropriate dose was injected daily or once s.c. near the site
of the tumour. Tumours were observed daily for signs of
necrosis and measured once weekly with calipers. The
tumour size indices shown in the figures are a multiplication
of the two largest tumour diameters at right angles to each
other.
Histology
Tumour samples were fixed in buffered formalin and embed-
ded in paraffin. Sections were cut at 5 im and stained with
haematoxylin and eosin. In certain experiments. samples were
fixed in 2.5% glutaraldehyde in Sorensen's phosphate buffer
and processed for electron microscopy using standard proce-
dures. One micron toluidine blue sections were used to select
representative areas for ultrastructural investigation.
RN.4 preparation and cD.NA sYnthesis
RNA was isolated bv a single extraction with guanidinium
thiocyanate phenol chloroform mixture as described (Chom-
czynski and Sacchi. 1987). Total RNA (5 jg) was incubated
for 30 min at 37'C in 40 mm Tris-HCl pH 7.5, 10 mM sodium
chloride. 6 mm magnesium chloride and 2.5 units of RQ1
DNAse (Promega. USA) in order to remove any con-
taminating genomic DNA from the preparations. After
phenol chloroform extraction and ethanol precipitation,
pellets were resuspended in water. Synthesis of the first
strand of cDNA was performed according to the instructions
delivered with the cDNA Synthesis Kit (Boehringer Mann-
heim. Switzerland). using random primers and avian myeloid
leukaemia virus (AMV) reverse transcriptase (10 units per
sample). After 1 h incubation at 42'C. samples were diluted
with water to a total volume of 50 jil. heat inactivated and
kept frozen (-20'C) until use.
Polvmerase chain reaction analysis
Aliquots of 2 jil of cDNA (the equivalent of 200 ng of total
RNA) were amplified in a final volume of 25 jIl using the
Gene-Amp kit (Perkin Elmer. Norwalk. USA). in the
presence of 5 jiCi of [a- 2PIdCTP (3000 Ci mmol-'. Amer-
sham) and 2.5 units of ampliTaq (Perkin Elmer Cetus). Sam-
ples were overlaid with mineral oil and amplified at 94°C for
5 mmn. 60'C for 1 min and 72°C for 30 s followed by 35 cycles
at 94'C for 30 s. 60'C for 1 mmn and 72'C for 30 s. The
termination cycle consisted of one cycle at 94'C for 30 s.
60'C for 1 min and 72'C for 10 mmn. PCR was carried out in
an automated DNA Thermal Cycler (Techne, Cambnrdge,
UK). in the presence of 0.2!um of each pnrmer. The following
pnmers were used:
GAPDH 1. 5'-TGA AGG TCG GTG TGA ACG GAT
TTG G-3'
GADPH 2. 5'-ACG ACA TAC TCA GCA CCA GCA TCA
C-3'
TNF-a 1. 5'-CCC GAC TAC GTG CTC CTC-3'
TNF-a 2. 5'-GAC CTG CCC GGA CTC CGC-3'
TNF receptor 55 kDa 1. 5'-CCG GGC CAC CTG GTC
CG-3'
TNF receptor 55 kDa 2. 5'-CAA GTA GGT TCC TTT
GTG-3'
TNF receptor 75 kDa 1. 5'-GAC GAA TTC ATG GAG
TAG GCC TTG AGC-3'
TNF receptor 75 kDa 2. 5'-TAA GGA TCC CTG AGA
CGG ACA CTC CTC-3'
ICAM-1 15' CAA CTG GAA GCT GTT TGA GCT G-3'
ICAM-1 2 5'-TAG CTG GAA GAT CGA AAG TCC G-3'
VCAM-1 1 5'-CAA GGG TGA CCA GCT CAT GA-3'
VCAM-1 2 5'-TGT GCA GCC ACC TGA GAT CC-3'
P-Selectin 1 5'-ACG AGC TGG ACG GAC CCG-3'
P-Selectin 2 5'-GGC TGG CAC TCA AAT TTA CAG C-3'
The glyceraldehyde phosphatase dehydrogenase (GAPDH)
primers recognise both human and murine GAPDH. the
remaining primers are all based on published murine
sequences. IL-6 primers were purchased from Clontech
(Clontech Laboratories. Palo Alto, CA, USA). One-half of
the reaction was electrophoresed on I1% agarose gels and the
appropriate bands revealed by ethidium bromide staining of
the gel.
Relative quantitation was achieved by subjecting parallel
samples to amplification in subsaturating conditions of the
constitutively expressed GAPDH gene and the specific
cytokine. receptor or adhesion molecule. The relative product
amounts were quantitated by measuring the incorporated
radioactivity of the specific bands from dried gels with a
Molecular Dynamics 400A Phosphorlmager. The values
obtained for each cytokine were normalised to the values
obtained by measuring the incorporated radioactivity in the
corresponding GAPDH amplification products. Under the
conditions used there was a linear relationship between the
initial amount of RNA and the PCR signal.-It should be
emphasised however that this protocol does not allow for a
precise determination of the exact amount of mRNA
molecules present in each sample.
Statistical analysis
The data were analysed for statistical significance between
groups using the Student's t-test; (two-tailed). Differences in
survival times were calculated by ANOVA.
Results
Effect of TNF-c and IFN-y on necrosis, tumour grow-th and
survival
We first measured the effects of varying doses of human
TNF-x and rat IFN-y on macroscopic necrosis, tumour
growth and treatment-related mortality (Table I). Only mice
receiving IFN-y in combination with TNF-a showed overt
haemorrhagic tumour necrosis which appeared approx-
imately 2 weeks after beginning the treatment. Mice injected
with the highest TNF-a and IFN-y doses (5 jig TNF-a and
50 x 103 U IFN-y) developed generalised vascular collapse
and tumour haemorrhagic necrosis so severe as to cause
ulceration of the overlying epidermis. Less severe tumour
necrotic patches, which generally resolved with scar forma-
tion, are observed in mice injected with 2.5 jig TNF-
a + 5 x I03 U IFN-y.
Tumour growth was inhibited with daily injections of
2.5 jig TNF-x. (P = 0.01 at 3 weeks, as compared to control,
Figure la). IFN-y (5 x 103 U) alone had no effect. Potentia-
Table I Effect of TNF-a and IFN-y on tumour growth. necrosis
and treatment-related mortality
TNF-a i.t. IF.V-y s.c. Effect on tumour Macroscopic
(Ag) x 103 units growth necrosis MortalitY
5 daily 0 Yes no no
0 50 daily No no no
5 daily 50 daily Yes yes (14)A yes
5 daily 5 daily Yes no no
2.5 daily 25 daily Yes no no
2.5 daily 5 daily Yes yes (14. 17)' no
2.5 daily 25 once Yes no no
Mice received daily cytokine treatments starting 14 days after
tumour cell inoculation. 'Day of appearance. bDays of appearance.
two separate expenments.tion of the anti-tumour growth effect was achieved with daily
injections of 2.5 iLg TNF-- in combination with 5 x I03 U
IFN-y (Figure la and b, P= 0.003 at 3 weeks, as compared
with control; P = 0.049 at 4 weeks, as compared with TNF-a
alone). As described above, this regimen was accompanied by
the appearance of tumour necrosis. Survival of treated mice
was prolonged as compared with controls (Figure 2). Some
animals had to be killed because overt haemorrhagic necrosis
developed, however. mice seemed otherwise healthy. Two-
way ANOVA test showed the difference in survival times was
highly significant (P = 0.004) as compared with controls.
Maximum inhibition of tumour growth in the absence of
macroscopic necrosis was obtained with 2.5 ig TNF-
a + 25 x I03 U IFN-y (P = 0.013 after 2 weeks of therapy,
P<0.0001 after 3 weeks, as compared with control, Figure
a
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Fgre 1 Effect of combined administration of TNF-a and IFN-
y on growth of 1068 human breast carcinoma xenografts. (a)
Effect of single and combined TNF-x and IFN-1 treatment. (b)
Effect of IFN-y dosage in combined treatment. Mice received
daily i.t. injections of human recombinant TNF-a and s.c. injec-
tions of recombinant rat IFN-y, starting 14 days after inoculation
of the tumour cells. Each experimental group consisted of seven
mice. Mean values from one representative experient are
shown. *Tumour size was significantly different from control
value. Differences were not caculated thereafter because control
animals had to be sacrificed at 2 weeks.
2.5 jg TNF-a + 25000 U IFN-y
~~~~~~~~~~~~~~~~I
l 2.5 gg TNF-a + 5000 U IFN-y
Control
1 5 10 15 20 25 30 35 40
Days of therapy
Fgre 2 Survival of mice receiving daily combined TNF-a and
IFN-y treatment. Each experimental group consisted of seven
mice. One representative experiment is shown. Animals injected
with 2.5iLg of TNF-a and 5000 U of IFN-y had to be sacrificed
at 37 days because they developed large haemorrhagic necrosis of
the area surrounding the tumour.
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ib). This regimen however, was not significantly different, in
terms of growth-inhibitory effect, to the 2.5 jig TNF-
x+ 5 x 03 U IFN-y regimen. One hundred per cent of
animals receiving this regimen survived 42 days after begin-
ning the therapy, that is 52 days after inoculation of the
tumour cells (P = 0.00004 as compared with controls) at the
time when the experiment was stopped (Figure 2). Total
tumour regression was observed in two out of seven mice
having received the 2.5gig TNF-a + 25 x 103 U IFN-y
therapy, 18 weeks after tumour inoculation.
In control mice light microscopy showed tumour cell
nodules consisting of interdigitating cells surrounded by a
stromal reaction containing macrophages, eosinophils,
polymorphonuclear cells, lymphocytes and small blood
vessels (Figure 3a). By contrast, tumours in mice treated with
2.5 iLg TNF-a and 25 x I03 U IFN-y showed complete regres-
sion after 35 days of therapy (Figure 3b). Only normal breast
ducts and fat cells of mouse origin were present, indicating
that tumour cells had not differentiated into breast tissue but
had altogether disappeared. Indication of apoptosis and
fibrinoid necrosis preceded these changes.
Vascular changes
By electron microscopy, numerous capillaries could be found
in the host cell stromal reaction area but none in the tumour
cell islands. Figure 4a shows part of a small capillary from a
control tumour. At 4 h after injection with 2.5 gLg TNF-a and
25 x 103 U IFN-y there was focal engorgement of tumour
capillaries with erythrocytes. Intraluniunal accumulation of
platelets and polymorphonuclear cells was also observed
(Figure 4b). At 6 h after therapy vessels were filled with
erythrocytes and thrombi, composed of degranulated
platelets and fibrin, were present. Accumulation of platelets
and their close association to endothelium was observed in
l
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Fire 3 Histological appearance of 1068 breast carcinoma. (a)
Tumour nodules (T) in control mice (after 14 days at which time
mice had to be sacrificed). (b) Normal murine breast ducts (D)
and fat cells (F) with no evidence of tumour cells in mice having
received 2.5 jug of TNFT- and 25 x 103 U of IFN--j for 35 days.
Haematoxylin and eosin (magnification x 65).
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areas of vascular injury (Figure 4c). After 24 h tumour capil-
lary endothelial cells had disappeared, although the basal
lamnina appeared to be intact (Figure 4d). Not all capillaries
in treated tumours exhibited these changes; some capillaries
showed no intraluminal erythrocyte accumulation and in
others the basal lamina had disappeared. In general, the
areas of vascular damage tended to be focal and associated
with areas of tumour cell death. These changes were not
observed in normal skin injected with TNF-a and IFN-y nor
in tumours treated with either agent alone. No inflammatory
cell infiltrates were seen within the tumour mass in either
control or cytokine-injected mice.
Apoptosis and necrosis
As shown in Figure 5, the injection of 2.5 Lg TNF-a and
25 x I03 U IFN--y induced tumour cell death by two distinct
mechanisms. Certain cell were clearly apoptotic with charac-
teristic condensation of chromatin around the periphery of
the nucleus, together with round, less densely staining
Fugwe 4 Platelet aggreation and adhesion to vascular endothelium in an area of vascular injury. (a) Normal endotbelial cell (E).
(b) Platelet aggregation (P) and adherence to endothelium 4h after injection of 1068 xenoagraft with 2.5jg of TNF-x and
25 x IO' U of IFN-7. (c) After 6 h, intraluminal thrombus (T) composed of degranulated platelets and fibrin in area ofendothelial
cell damage. (d) At 24 h. disappearance of endothelium, only the basal lamina remaining (B). Bar = 1 jum.nucleolar fibrillar centres. Other cells appeared to be in the
early stages of chromatin condensation of apoptosis. Secon-
dary necrosis with a rather haphazard pattern of disintegra-
tion of the cytoplasm could also be found. Early and late
stages of necrosis, without evidence of prior apoptosis also
appeared. Finally, cell fragments were present which could be
due to late stage necrosis, although the changes were far too
advanced to determine whether there was any prior apop-
tosis.
C}vtokines, cytokine receptors and adhesion molecules
Total RNA from tumour was extracted from two mice at
each time point following injection with either 2.5 ;Lg TNF-(,
25 x I03 U IFN-y or both. mRNA expression was analysed
by RT-PCR, using murine-based primers, so as to study
cytokine and adhesion molecule expression changes in the
host. To calculate the relative fold induction of mRNA.
PCR-generated bands were quantitated with a Phos-
A44-bou dcbdsd TNF-z and IFN1y in Wm
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phorlmager and the values obtained were corrected by ratio
to their corresponding GAPDH amplification products.
Induction was then estimated as the fold change compared
with baseline (control) values. Given the inherent variations
due to the technique, only increases above 5-fold or higher
were considered significant. Low levels of murine TNF-x
mRNA were detected in BSA-injected control 1068 tumours
(not shown). Following the injection of either cytokine alone
or in combination, endogenous murine TNF-x mRNA exp-
ression rose rapidly. Maximal induction of TNF-a mRNA
appeared between 30 min and 1 h after therapy (Figure 6).
Both TNF-x receptors 55 kDa and 75 kDa were induced by
all treatments, with highest mRNA expression at 3 h post-
a
TNF-a
Fiwe 5 Necrosis and apoptosis of 1068 breast carcinoma cells
in vivo. (a) Normal tumour cells. (b) Presence of early apoptotic
cells (A), early stage of apoptosis (EA). secondary necrosis (SN).
early stage necrosis (EN) and advanced necrosis (N) in tumours
24 h after injection with 2.5 jig of TNF-c and 25 x I03 U IFN-y.
Bar= 1 ;im.
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Fugwe 6 Effect of TNF-a and IFN-y on (a) TNF-a (b) TNF R
55 kDa and (c) TNF R 75 kDa mRNA levels. Tumour RNA was
extracted from two mice at different times following injection
with 2.5;.g of TNF-a or 25 x 101 U of IFN-y or both. BSA-
injected animals served as control. Parallel samples were
amplified for TNF-c and GAPDH and the specific PCR-
generated fragments visualised by ethidium bromide staining of
the gel. To show the fold induction, TNF-z, TNF R 55 kDa- and
TNF R 75 kDa-specific fragments were amplified by RT-PCR, in
the presence of a radiolabelled nucleotide. Appropriate bands
were quantitated with a PhosphorImager and the values obtained
were corrected by ratio to GAPDH amplification products (upper
right and below). Values shown are the mean of two mice per
treatment per time point and represent the fold difference as
compared with control values. [l. IFN-'y; m, TNF-a ,
TNF-a and IFN-y.
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Fiure 7 Effect of TNF-Z and IFN-y on IL-6. ICAM-1. VCAM-1 and P-selectin mRNA levels. Tumour RNA was extracted from
two mice at different times following injection with 2.5 ,Lg of TNF-a or 25 x 103 U of IFN-y or both. BSA-injected animals served
as control. IL-6. ICAM-1. VCAM-1 and P-selectin mRNA expression was analysed by RT-PCR, in the presence of a radiolabelled
nucleotide. Appropnrate bands were quantitated with a Phosphorlmager and the values obtained were corrected by ratio to
GAPDH amplification products. Values shown are the mean of two mice per treatment per time point and represent the fold
difference as compared with control values. [. IFN-y; M. TNF-x; M, TNF-a and IFN-y.
therapy (Figure 6). Intercellular adhesion molecule-I (ICAM-
1) mRNA was also detected in control tumours and .was
strongly induced by either therapy, with maximum mRNA
levels appeanrng 3 h after injection, returning to baseline
levels after 24 h (Figure 7). Vascular cell adhesion molecule-I
(VCAM-1) mRNA levels were almost undetectable in control
tumours. mRNA expression was induced by either cytokine
alone or in combination, with highest VCAM-1 mRNA expp-
ression reached 6 h post therapy. P-selectin mRNA was pres-
ent in low levels in control tumours and was also rapidly
induced by either treatment. Maximum induction was
achieved I h after therapy (Figure 7). IL-6 mRNA was very
strongly induced by TNF-a treatment but not by IFN-y after
1 h. Dual therapy did not affect significantly the expression
of IL-6, as compared with TNF-a alone (Figure 7).
Discus
In the present study we have shown that high-dose human
recombinant TNF-x, delivered locally, was able to inhibit
tumour growth. Human TNF--x can only act through the
55 kDa receptor but not the 75 kDa receptor in mice
(Brouckaert et al. 1993). The TNF R 75 kDa has been
shown to mediate many of the vascular effects of TNF-a,
such as neutrophil adhesion to the endothelium and E-
selectin expression (Barbara et al., 1994). However, we have
observed a very early induction of murine TNF-a mRNA
(30mn) in response to human recombinant TNF-a or rat
IFN-y therapy, which in turn may account for specifically
75 kDa-mediated effects. Potentiation of the anti-tumour
effect was achieved by combining TNF-a with systemically
administered IFN-y. The role of IFN-'y in the potentiation of
the anti-tumour effects of TNF-x is critical and is well
documented (Fransen -et al., 1986; Chen et al., 1987). In
agreement with our observations, Thom et al. (1992) have
reported effective treatment of MCA sarcomas in mice with
paralesional TNF-a and IFN-y therapy, as well as local skin
necrosis leading to treatment-related mortality. In patients,
treatment of malignant melanomas with TNTF-, IFN-y and
melphalan by isolated limb perfusion has provided controver-
sial results. On the one hand, investigators reported a high
success rate in a majority of patients with melanoma,
squamous cell carcinoma and soft tissue carcinoma (Lienard
et al., 1992, 1994; Eggermont et al., 1993). However, other
groups following the same protocol have not been able to
obtain similar results (Vaghni et al., 1994).
Tumour regression in response to TNF-a can be due to
direct and indirect effects, many of which may be potentiated
by IFN-y. Among its direct effects TNF-a can induce both
apoptotic and necrotic forms of cell lysis (Laster et at., 1988;
Bellomo et al., 1992). In the present report, we have shown
necrosis and apoptosis of 1068 tumour cells. It is not clear,
however, whether necrosis was the direct result of TNF-a, or
the indirect result of vascular damage, oxygen starvation,
cytotoxic actions of other host stromal cells induced by the
therapy or a combination of these. IFN-y, which can also
induce either pathological or physiological cell death (Aune
and Pogue, 1989) could not have caused tumour cell death
directly, since rat IFN--y does not act on human cells.
Vascular damage is now widely accepted as a mechanism
of the tumoricidal actions of TNF-a. This cytokine has been
reported to have direct cytotoxic effects on the vascular
endothelium (Watanabe et al., 1988), to induce apoptosis of
endothelial cells in vitro (Robaye et al.. 1991) and to
modulate endothelial procoagulant properties (Nawroth and
Stern, 1986). Thrombus formation and fibrin deposition are
common histological findings in TNF-i-treated Meth A sar-
comas (Shimomura et al., 1988). It is also worth noting that
anticoagulants have been shown to inhibit the anti-tumoural
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effects of TNF-x (Shimomura et al.. 1988). In Friend
leukaemia tumours and fibrosarcomas injected
peritumourally with TNF-a, there is evidence of vascular
congestion, intraluminal thrombi and the accumulation of
platelets, in association with marked damage of endothelial
cells before the appearance of necrotic areas (Proietti et al.,
1988). Injury to endothelial cells and accumulation of neut-
rophils was also reported after TNF-x and hyperthermia
therapy in the RIF-l fibrosarcoma (Srinivasan et al., 1990).
Furthermore, Renard et al. (1994) have observed early
endothehal cell activation and polymorphonuclear cell
invasion preceding necrosis in human tumours treated with
high-dose TNF-a and IFN-y by ILP therapy. These histo-
logical descriptions correlate with our present observations of
intravascular accumulation of erythrocytes and neutrophils,
platelet adherence to the tumour vascular endothelium fol-
lowed by endothelial cell damage and haemorrhagic necrosis.
The question arises as to the actual mechanisms of
endothelial cell injury. Recent studies have provided evidence
for an unexpected role for platelets in mediating vascular
pathology. Grau et al. (1993) have demonstrated the pivotal
role played by platelets in cerebral malaria. In susceptible
animals, high circulating levels of TNF-a and increased local
production of IFN-y lead to the overexpression of ICAM-1
in brain microvascular endothelial cells. Leucocyte function
antigen-l (LFA-l)-bearing platelets then specifically adhere
to ICAM-1 and fuse with endothelial cells, causing irreversi-
ble damage and microhaemorrhages. It is tempting to
speculate that a similar sequence of events leads to
endothelial destruction and haemorrhagic necrosis in the
1068 tumour following high-dose local TNF-a and IFN-y
therapy.
TNF-a and IFN-y can promote the expression of overlapp-
ing sets of adhesion molecules (Pober et al., 1986). Following
cytokine therapy, we noted the increased expression of
endogenous TNF, TNF receptor 55 kDa. TNF receptor
75 kDa, ICAM-1 VCAM-1, P-selectin and IL-6 mRNA
levels. To the best of our knowledge, this is the first extensive
study investigating the kinetics of mRNA expression for
these cytokines, receptors and adhesion molecules in
tumours. In general, low levels of ICAM-1 and VCAM-1 can
be observed in normal vascular endothelium and their exp-
ression is stimulated by cytokine therapy (reviewed in
Bevilacqua 1993). VCAM-1, as well as P-selectin, can also be
present in non-vascular cells. Mediators that stimulate P-
selectin expression can cause endothelial cell retraction or
damage resulting in increased permeability. Furthermore,
higher levels of ICAM-1 mRNA in response to TNF-a and
IFN-y therapy could be involved in the adherence of platelets
to the tumour vascular endothelium and the ensuing damage,
by analogy with the pathology observed in the munrne model
of cerebral malaria (Grau et al., 1993). However, this alone
cannot account for tumour regression since IFN-y has no
activity on its own. ICAM-l can also bind LFA-l-expressing
neutrophils and monocytes. When neutrophils adhere to
activated endothelium they can secrete proteolytic enzymes
which are able to destroy the extracellular membrane (Cajot
et al.. 1986). The induction and amplification of adhesion
molecule expression. namely VCAM-1. ICAM-l and ELAM-l
have also been reported in melanoma and sarcoma patients
treated with high dose TNF-m. IFN-y and melphalan (Renard
et al.. 1994). The specific induction of IL-6 by TNF-z alone
or in combination with IFN-y is of interest. After continuous
infusion of TNF-a and IFN-y, elevated circulating levels of
IL-6 have been reported (Brouckaert et al.. 1989). In the
study presented here. IL-6 could thus contribute to the anti-
tumoural effect, as shown before in other murine tumour
models (Mule et al.. 1990). Very recently. increased serum
11-6. ICAM-1 and TNF receptor 55 kDa concentrations have
been detected in patients undergoing TNF-a IFN-y
melphalan therapy by ILP (Thom et al.. 1995).
In conclusion, the present study shows that we have been
able to produce a useful model of cytokine-induced tumour
growth arrest and necrosis. comparable with ILP (Lienard et
al.. 1992). The differences between human ILP and the pres-
ent model should however be stressed: in ILP, human TNF-a
is injected systemically, in combination with human IFN-y
and melphalan. We inject human TNF-a intratumourally and
IFN-y systemically. In ILP, a human tumour in a human
host is treated, whereas we treat a human xenograft in an
immunocompromised mouse. Notwithstanding the limita-
tions imposed by our model. we found it to reproduce certain
key aspects of ILP: destruction of tumour cells by necrosis,
endothelial cell activation, induction of adhesion molecule
expression and specific damage of the tumour vasculature in
response to TNF-a and IFN-y therapy. As for ILP, it is
tempting to speculate that the association of platelets and
neutrophils with areas of vascular injury. via the induction of
specific adhesion molecules on the host endothelium. may
play a crucial role in mediating these anti-tumoural actions.
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